Rallybio (NASDAQ:RLYB) Upgraded to “Hold” at Wall Street Zen

Rallybio (NASDAQ:RLYB) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Saturday, September 27th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Rallybio presently has a consensus rating of “Reduce” and a consensus target price of $5.00.

Rallybio Price Performance

NASDAQ:RLYB opened at $0.56 on Friday. The stock has a market cap of $23.60 million, a P/E ratio of -0.60 and a beta of -1.10. Rallybio has a one year low of $0.22 and a one year high of $1.24. The company has a fifty day moving average price of $0.56 and a 200 day moving average price of $0.44.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. The firm had revenue of $0.21 million for the quarter. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. As a group, equities research analysts anticipate that Rallybio will post -1.34 EPS for the current year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.